Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: iron oxide red; hyprolose; povidone; microcrystalline cellulose; silicon dioxide; crospovidone; polysorbate 80; maize starch; hypromellose phthalate; pregelatinised maize starch; light magnesium oxide; sucrose; methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; glyceryl monostearate; macrogol 6000; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; light magnesium oxide; crospovidone; sucrose; glyceryl monostearate; iron oxide red; methacrylic acid - ethyl acrylate copolymer (1:1); maize starch; macrogol 6000; povidone; polysorbate 80; pregelatinised maize starch; purified talc; silicon dioxide; hypromellose phthalate; hyprolose; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 44.528 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: silicon dioxide; polysorbate 80; pregelatinised maize starch; crospovidone; macrogol 6000; microcrystalline cellulose; hypromellose phthalate; sucrose; hyprolose; glyceryl monostearate; light magnesium oxide; methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; iron oxide red; maize starch; povidone; macrogol 400; titanium dioxide; hypromellose - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 44.528 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: light magnesium oxide; silicon dioxide; sucrose; methacrylic acid - ethyl acrylate copolymer (1:1); maize starch; macrogol 6000; polysorbate 80; purified talc; iron oxide red; crospovidone; povidone; hyprolose; microcrystalline cellulose; pregelatinised maize starch; glyceryl monostearate; hypromellose phthalate; macrogol 400; titanium dioxide; hypromellose - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: hypromellose phthalate; maize starch; glyceryl monostearate; sucrose; iron oxide red; hyprolose; macrogol 6000; silicon dioxide; povidone; polysorbate 80; methacrylic acid - ethyl acrylate copolymer (1:1); light magnesium oxide; microcrystalline cellulose; crospovidone; purified talc; pregelatinised maize starch; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 44.528 mg (equivalent: esomeprazole, qty mg) - tablet, enteric coated - excipient ingredients: crospovidone; hypromellose phthalate; maize starch; purified talc; silicon dioxide; light magnesium oxide; povidone; glyceryl monostearate; iron oxide red; methacrylic acid - ethyl acrylate copolymer (1:1); sucrose; pregelatinised maize starch; macrogol 6000; hyprolose; polysorbate 80; microcrystalline cellulose; macrogol 400; titanium dioxide; hypromellose - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 44.5 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: iron oxide red; microcrystalline cellulose; polysorbate 80; triethyl citrate; synthetic paraffin; titanium dioxide; crospovidone; hypromellose; purified talc; glyceryl monostearate; methacrylic acid copolymer; magnesium stearate; hyprolose; sodium stearylfumarate; macrogol 6000; maize starch; sucrose - nexium is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with nexium iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: -healing of duodenal ulcer associated with helicobacter pylori. -eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 22.3 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: purified talc; glyceryl monostearate; iron oxide yellow; hypromellose; microcrystalline cellulose; methacrylic acid copolymer; synthetic paraffin; iron oxide red; triethyl citrate; macrogol 6000; polysorbate 80; crospovidone; titanium dioxide; magnesium stearate; hyprolose; sodium stearylfumarate; maize starch; sucrose - nexium is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with nexium iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: -healing of duodenal ulcer associated with helicobacter pylori. -eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 44.5 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: iron oxide red; microcrystalline cellulose; polysorbate 80; triethyl citrate; synthetic paraffin; titanium dioxide; crospovidone; hypromellose; purified talc; glyceryl monostearate; methacrylic acid copolymer; magnesium stearate; hyprolose; sodium stearylfumarate; macrogol 6000; maize starch; sucrose - esopreze is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with esopreze iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: -healing of duodenal ulcer associated with helicobacter pylori. -eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 22.3 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: purified talc; glyceryl monostearate; iron oxide yellow; hypromellose; microcrystalline cellulose; methacrylic acid copolymer; synthetic paraffin; iron oxide red; triethyl citrate; macrogol 6000; polysorbate 80; crospovidone; titanium dioxide; magnesium stearate; hyprolose; sodium stearylfumarate; maize starch; sucrose - esopreze is indicated for: gastro-oesophageal reflux disease (gord) -treatment of erosive reflux oesophagitis -long-term management of patients with healed oesophagitis to prevent relapse -symptomatic treatment of gastro-oesophageal reflux disease (gord) patients requiring nsaid therapy: -short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy. -prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk. prevention of rebleeding of gastric or duodenal ulcers following treatment with esopreze iv solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion. in combination with appropriate antibiotics for: -healing of duodenal ulcer associated with helicobacter pylori. -eradication of helicobacter pylori in patients with active or healed peptic ulcer.